Glioblastoma

Research team describes novel tumor treatment

In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos in Scientific Reports has been published.

Nov 24, 2015
popularity90 comments 0

Genome misfolding unearthed as new path to cancer

In a landmark study, researchers from the Broad Institute and Massachusetts General Hospital reveal a completely new biological mechanism that underlies cancer. By studying brain tumors that carry mutations in the isocitrate ...

Dec 23, 2015
popularity29 comments 1

First look at how astrocytes function in humans

Pretty much everything happening in the brain would fail without astrocytes. These star-shaped glial cells are known to have a critical role in synapse creation, nervous tissue repair, and the formation of the blood-brain ...

Dec 10, 2015
popularity95 comments 1

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Study finds possible new jet-lag treatment

Exposing people to short flashes of light while they're sleeping could provide a fast and efficient method of preventing jet lag, according to a study by researchers at the Stanford University School of Medicine.

Gut environment could reduce severity of malaria

Microorganisms in the gut could play a role in reducing the severity of malaria, according to a new study co-authored by researchers at the University of Tennessee, Knoxville, and the University of Louisville.

Timebomb in the testicles investigated

Oxford scientists have for the first time been able to identify the origins of some severe disease-causing mutations within the testicles of healthy men. This discovery will help our understanding of how certain serious genetic ...

Study examines evolution of cancer

A novel Yale study answers age-old questions about how cancers spread by applying tools from evolutionary biology. The new insights will help scientists better understand the genetic origins of tumor metastases, and lead ...

Sleep deprivation linked to false confessions

Sleep-deprived people are much more likely to sign false confessions than rested individuals, according to a groundbreaking study that has important implications for police interrogation practices.